These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 130136)

  • 1. Therapeutic studies in NZB/W mice. IV. Effect of combination drug therapy on immune complex deposition.
    Gelfand MC; Schur PH; Asofsky R; Steinberg AD
    Arthritis Rheum; 1976; 19(1):43-8. PubMed ID: 130136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide protection in NZB/NZW disease. Mechanisms and therapeutic regimens.
    Morris AD; Esterly J; Chase G; Sharp GC
    Arthritis Rheum; 1976; 19(1):49-55. PubMed ID: 130137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy.
    Steinberg AD; Gelfand MC; Hardin JA; Lowenthal DT
    Arthritis Rheum; 1975; 18(1):9-14. PubMed ID: 1115749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic studies in NZB-W mice. I. Synergy of azathioprine, cyclophosphamide and methylprednisolone in combination.
    Gelfand MC; Steinberg AD; Nagle R; Knepshield JH
    Arthritis Rheum; 1972; 15(3):239-46. PubMed ID: 5031608
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic studies in NZB-W mice. II. Relative efficacy of azathioprine, cyclophosphamide and methylprednisolone.
    Gelfand MC; Steinberg AD
    Arthritis Rheum; 1972; 15(3):247-52. PubMed ID: 5031609
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW mice.
    Hahn BH; Knotts L; Ng M; Hamilton TR
    Arthritis Rheum; 1975; 18(2):145-52. PubMed ID: 1131283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic studies of autoimmunity in New Zealand mice. IV. Contribution of NZB and NZW genes to the spontaneous occurrence of retroviral gp70 immune complexes in (NZB X NZW)F1 hybrid and the correlation to renal disease.
    Maruyama N; Furukawa F; Nakai Y; Sasaki Y; Ohta K; Ozaki S; Hirose S; Shirai T
    J Immunol; 1983 Feb; 130(2):740-6. PubMed ID: 6217253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single and multiple drug therapy in autologous immune complex nephritis in rats.
    Kupor LR; Lowance DC; McPhaul JJ
    J Lab Clin Med; 1976 Jan; 87(1):27-36. PubMed ID: 128575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E1 treatment of NZB/NZW F1 hybrid mice. II. Prevention of glomerulonephritis.
    Zurier RB; Damjanov I; Sayadoff DM; Rothfield NF
    Arthritis Rheum; 1977; 20(8):1449-56. PubMed ID: 144506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Ig mu-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB x NZW)F1 mice.
    Wellmann U; Letz M; Schneider A; Amann K; Winkler TH
    Int Immunol; 2001 Dec; 13(12):1461-9. PubMed ID: 11717187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of NZB/NZW murine nephritis by administration of a syngeneic monoclonal antibody to DNA. Possible role of anti-idiotypic antibodies.
    Hahn BH; Ebling FM
    J Clin Invest; 1983 Jun; 71(6):1728-36. PubMed ID: 6223048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribavirin treatment in murine autoimmune disease. I. Therapeutic efficacy and effect on the immune response.
    Klassen LW; Williams GW; Reinertsen JL; Gerber NL; Steinberg AD
    Arthritis Rheum; 1979 Feb; 22(2):145-54. PubMed ID: 33680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulated autoantibody response and increased longevity in NZB/NZW mice treated with cyclophosphamide and tilorone.
    Walker SE; Anver MR
    Clin Exp Immunol; 1978 Sep; 33(3):453-62. PubMed ID: 737897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of immune complex nephritis in NZB/WF1 mice by a prostacyclin analogue.
    Utsunomiya Y; Ogura M; Kawamura T; Mitarai T; Maruyama N; Sakai O
    Clin Exp Immunol; 1995 Mar; 99(3):454-60. PubMed ID: 7882569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-drug treatment of autologous immune complex glomerulonephritis.
    Fleuren GJ; Hoedemaeker PJ
    Clin Exp Immunol; 1980 Aug; 41(2):218-24. PubMed ID: 6449335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Animal models utilized in the research of autoimmune disease control: experimental therapy of glomerulonephritis in NZB/W F1 mice.
    Okudaira H; Terada E; Okudaira K
    Prog Clin Biol Res; 1987; 229():157-74. PubMed ID: 3601985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition.
    Schiffer L; Sinha J; Wang X; Huang W; von Gersdorff G; Schiffer M; Madaio MP; Davidson A
    J Immunol; 2003 Jul; 171(1):489-97. PubMed ID: 12817034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.
    Zoja C; Casiraghi F; Conti S; Corna D; Rottoli D; Cavinato RA; Remuzzi G; Benigni A
    Arthritis Rheum; 2007 May; 56(5):1629-37. PubMed ID: 17469145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The viral envelope glycoprotein of murine leukemia virus and the pathogenesis of immune complex glomerulonephritis of New Zealand mice.
    Yoshiki T; Mellors RC; Strand M; August JT
    J Exp Med; 1974 Oct; 140(4):1011-27. PubMed ID: 4279268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of lupus nephritis.
    Pollak VE
    Adv Nephrol Necker Hosp; 1976; 6():137-61. PubMed ID: 828444
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.